Download PDF
Horm Metab Res 2014; 46(05): 360-364
DOI: 10.1055/s-0033-1364003
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Assessment of Small C-Fiber Status for Screening of Oxidative Stress in Patients at Risk of Diabetes

E. Parfentyeva
1   University Clinic Carl Gustav Carus at the Technical University Dresden, Dresden, Germany
,
S. Saha
1   University Clinic Carl Gustav Carus at the Technical University Dresden, Dresden, Germany
,
V. T. Hjellset
2   Department of Preventive Medicine and Epidemiology, Institute of General Practice and Community Medicine, University of Oslo, Oslo, Norway
,
S. Kopprasch
1   University Clinic Carl Gustav Carus at the Technical University Dresden, Dresden, Germany
,
P. E. H. Schwarz
1   University Clinic Carl Gustav Carus at the Technical University Dresden, Dresden, Germany
3   German Center for Diabetes Research (DZD), Paul Langerhans Institute Dresden, Dresden, Germany
› Author Affiliations
Further Information

Publication History

received 03 September 2013

accepted 16 December 2013

Publication Date:
28 February 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Oxidized LDL (oxLDL), anti-oxLDL antibody (anti-oxLDL) and paraoxonase (PON1) are increasingly being reported to be associated with diabetic atherosclerosis. Oxidative stress could affect also small C-fibers innervating the sweat glands even in prediabetes. Hence it could be hypothesized that sweat dysfunction may be a predictor of oxidative stress status for early detection of diabetes. Ezscan, a new device, has recently been developed to measure the sweat function. Therefore, this study was aimed to determine the relevance of this Ezscan method to identify impairment in oxidative stress parameters. Plasma levels of oxLDL and anti-oxLDL were measured by enzyme immunoassay and ELISA respectively. Small C-fiber status was assessed by measurement of hand and foot sweat function with the help of Ezscan device and subsequent calculation of a risk score. Out of 82 subjects recruited in this study, 38 had impaired glucose tolerance and 6 had newly diagnosed diabetes mellitus. Ezscan risk score was significantly (p=0.004) correlated with oxLDL/anti-oxLDL ratio (0.32). Area under the curve (AUC) of receiver operating characteristics (ROC) analysis for detection of oxLDL/anti-oxLDL ratio (>0.12) was 0.76. For an Ezscan risk score of 50%, the sensitivity and specificity were 68% and 71% respectively. After adjustment for age and BMI, PON1 activity showed significant difference among the 3 risk groups defined by Ezscan risk score. Based on these results it may be concluded that Ezscan could be a useful screening tool in daily practice to assess alterations in oxidative stress parameters in individuals at risk of developing diabetes.

Key words

sweat dysfunction - oxidized LDL - antioxidized LDL antibody - paraoxonase - atherosclerosis
 

  • References

  • 1 Stocker R, Keaney Jr JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-1478
    CrossrefPubMedGoogle Scholar
  • 2 Saha S, Schwarz PE, Bergmann S, Bornstein SR, Graessler J, Kopprasch S. Circulating very-low-density lipoprotein from subjects with impaired glucose tolerance accelerates adrenocortical cortisol and aldosterone synthesis. Horm Metab Res 2013; 45: 169-172
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Piarulli F, Lapolla A, Sartore G, Rossetti C, Bax G, Noale M, Minicuci N, Fiore C, Marchioro L, Manzato E, Fedele D. Autoantibodies against oxidized LDLs and atherosclerosis in type 2 diabetes. Diabetes Care 2005; 28: 653-657
    CrossrefPubMedGoogle Scholar
  • 4 Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-887
    CrossrefPubMedGoogle Scholar
  • 5 Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995; 115: 243-253
    CrossrefPubMedGoogle Scholar
  • 6 Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107: 2775-2779
    CrossrefPubMedGoogle Scholar
  • 7 Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962
    CrossrefPubMedGoogle Scholar
  • 8 Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553-1579
    CrossrefPubMedGoogle Scholar
  • 9 Yajnik CS, Kantikar V, Pande A, Deslypere JP, Dupin J, Calvet JH, Bauduceau B. Screening of cardiovascular autonomic neuropathy in patients with diabetes using non-invasive quick and simple assessment of sudomotor function. Diabetes Metab 2013; 39: 126-131
    CrossrefPubMedGoogle Scholar
  • 10 Schwarz PE, Li J, Lindstrom J, Tuomilehto J. Tools for predicting the risk of type 2 diabetes in daily practice. Horm Metab Res 2009; 41: 86-97
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Schwarz PE, Albright AL. Prevention of type 2 diabetes: the strategic approach for implementation. Horm Metab Res 2011; 43: 907-910
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Lindstrom J, Neumann A, Sheppard KE, Gilis-Januszewska A, Greaves CJ, Handke U, Pajunen P, Puhl S, Polonen A, Rissanen A, Roden M, Stemper T, Telle-Hjellset V, Tuomilehto J, Velickiene D, Schwarz PE, Acosta T, Adler M, AlKerwi A, Barengo N, Barengo R, Boavida JM, Charlesworth K, Christov V, Claussen B, Cos X, Cosson E, Deceukelier S, Dimitrijevic-Sreckovic V, Djordjevic P, Evans P, Felton AM, Fischer M, Gabriel-Sanchez R, Gilis-Januszewska A, Goldfracht M, Gomez JL, Greaves CJ, Hall M, Handke U, Hauner H, Herbst J, Hermanns N, Herrebrugh L, Huber C, Huhmer U, Huttunen J, Jotic A, Kamenov Z, Karadeniz S, Katsilambros N, Khalangot M, Kissimova-Skarbek K, Kohler D, Kopp V, Kronsbein P, Kulzer B, Kyne-Grzebalski D, Lalic K, Lalic N, Landgraf R, Lee-Barkey YH, Liatis S, Lindstrom J, Makrilakis K, McIntosh C, McKee M, Mesquita AC, Misina D, Muylle F, Neumann A, Paiva AC, Pajunen P, Paulweber B, Peltonen M, Perrenoud L, Pfeiffer A, Polonen A, Puhl S, Raposo F, Reinehr T, Rissanen A, Robinson C, Roden M, Rothe U, Saaristo T, Scholl J, Schwarz PE, Sheppard KE, Spiers S, Stemper T, Stratmann B, Szendroedi J, Szybinski Z, Tankova T, Telle-Hjellset V, Terry G, Tolks D, Toti F, Tuomilehto J, Undeutsch A, Valadas C, Valensi P, Velickiene D, Vermunt P, Weiss R, Wens J, Yilmaz T. Take action to prevent diabetes – the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res 2010; 42 (Suppl. 01) S37-S55
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Schwarz PE, Brunswick P, Calvet JH. EZSCAN a new tool to detect diabetes risk. Br J Diabetes Vasc Dis 2011; 11: 204-209
    CrossrefPubMedGoogle Scholar
  • 14 Gin H, Baudoin R, Raffaitin CH, Rigalleau V, Gonzalez C. Non-invasive and quantitative assessment of sudomotor function for peripheral diabetic neuropathy evaluation. Diabetes Metab 2011; 37: 527-532
    CrossrefPubMedGoogle Scholar
  • 15 Calvet JH, Dupin J, Winiecki H, Schwarz PEH. Assessment of Small Fiber Neuropathy through a Quick, Simple and Non Invasive Method in a German Diabetes Outpatient Clinic. Exp Clin Endocr Diab 2013; 121: 80-83
    PubMedGoogle Scholar
  • 16 Schwarz PE, Towers GW, Fischer S, Govindarajalu S, Schulze J, Bornstein SR, Hanefeld M, Vasseur F. Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic variation in the ADIPOQ gene promoter. Diabetes Care 2006; 29: 1645-1650
    CrossrefPubMedGoogle Scholar
  • 17 Casellini CM, Parson HK, Richardson MS, Nevoret ML, Vinik AI. Sudoscan, a noninvasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction. Diabetes Technol Therap 2013; 15: 948-953
    CrossrefPubMedGoogle Scholar
  • 18 Schwarz PEH, Brunswick P, Calvet JH. EZSCAN a new technology to detect diabetes risk. Br J Diabetes Vascul Dis 2011; 11: 204-209
    PubMedGoogle Scholar
  • 19 Grandinetti A, Chow DC, Sletten DM, Oyama JK, Theriault AG, Schatz IJ, Low PA. Impaired glucose tolerance is associated with postganglionic sudomotor impairment. Clin Auton Res 2007; 17: 231-233
    CrossrefPubMedGoogle Scholar
  • 20 Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-2293
    CrossrefPubMedGoogle Scholar
  • 21 Illigens BM, Gibbons CH. Sweat testing to evaluate autonomic function. Clin Auton Res 2009; 19: 79-87
    CrossrefPubMedGoogle Scholar
  • 22 Papanas N, Giassakis G, Papatheodorou K, Papazoglou D, Monastiriotis C, Christakidis D, Piperidou H, Maltezos E. Sensitivity and specificity of a new indicator test (Neuropad) for the diagnosis of peripheral neuropathy in type 2 diabetes patients: a comparison with clinical examination and nerve conduction study. J Diabetes Complicat 2007; 21: 353-358
    CrossrefPubMedGoogle Scholar
  • 23 Nakhjavani M, Khalilzadeh O, Khajeali L, Esteghamati A, Morteza A, Jamali A, Dadkhahipour S. Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids 2010; 45: 321-327
    CrossrefPubMedGoogle Scholar
  • 24 Pawlak K, Mysliwiec M, Pawlak D. Oxidized LDL to autoantibodies against oxLDL ratio – the new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients. Atherosclerosis 2012; 224: 252-257
    CrossrefPubMedGoogle Scholar
  • 25 Yajnik CS, Kantikar VV, Pande AJ, Deslypere JP. Quick and simple evaluation of sudomotor function for screening of diabetic neuropathy. ISRN Endocrinol 2012; 2012: 103714
    PubMedGoogle Scholar
  • 26 Sun K, Liu Y, Dai M, Li M, Yang Z, Xu M, Xu Y, Lu J, Chen Y, Liu J, Ning G, Bi Y. Accessing autonomic function can early screen metabolic syndrome. PloS One 2012; 7: e43449
    CrossrefPubMedGoogle Scholar
  • 27 Muller G, Parfentyeva E, Olschewsky J, Bornstein SR, Schwarz PE. Assessment of small fiber neuropathy to predict future risk of type 2 diabetes. Prim Care Diabetes 2013; 7: 269-273
    CrossrefPubMedGoogle Scholar
  • 28 Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J, Kanda H, Emoto M, Kawagishi T, Morii H. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000; 148: 171-177
    CrossrefPubMedGoogle Scholar
  • 29 Che J, Li G, Wang W, Li Q, Liu H, Chen K, Liu T. Serum autoantibodies against human oxidized low-density lipoproteins are inversely associated with severity of coronary stenotic lesions calculated by Gensini score. Cardiol J 2011; 18: 364-370
    PubMedGoogle Scholar
  • 30 Kara C, Cetinkaya S, Sezgin N, Kinik ST. The effects of metabolic control on oxidized low-density lipoprotein antibodies in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2008; 9: 17-22
    CrossrefPubMedGoogle Scholar
  • 31 Lu C, Gao Y, Zhou H, Tian H. The relationships between PON1 activity as well as oxLDL levels and coronary artery lesions in CHD patients with diabetes mellitus or impaired fasting glucose. Coron Artery Dis 2008; 19: 565-573
    CrossrefPubMedGoogle Scholar
  • 32 Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q, Mayr A, Witztum JL, Kiechl S. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am College Cardiol 2012; 60: 2218-2229
    CrossrefPubMedGoogle Scholar